MedTrace Logo

Effect of Milnacipran on Pain in Fibromyalgia

NCT01288807 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2019-09-24

Study results available
· View outcomes & findings →

Summary

The investigators want to study the effects of milnacipran treatment on neurotransmitter release in fibromyalgia.

Conditions

  • Fibromyalgia

Interventions

DRUG

Milnacipram

Titration to 200mg PO daily

Sponsors & Collaborators

Principal Investigators

  • Tobias Moeller-Bertram, MD, PhD, MAS · University of California, San Diego

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01288807 on ClinicalTrials.gov